Abstract. Interleukin-32 (IL-32) is a pro-inflammatory cytokine and its effects in various inflammatory diseases have been investigated. However, the role of IL-32 on atherosclerosis, an inflammatory disease, remains unknown. The present study examined the use of IL-32α, the most abundant transcript of IL-32, in the treatment of oxidized low-density lipoprotein (ox-LDL)-stimulated THP-1 macrophages for 24 h, which simulates a foam cell formation model. The effect of IL-32α (20, 50 and 100 ng/ml) on lipid deposition in the macrophages was analyzed using Oil Red O staining, while the cholesterol efflux on apolipoprotein A-I was also measured. The mRNA and protein expression levels of peroxisome proliferator-activated receptor γ (PPARγ), liver X receptor α (LXRα), ATP-binding cassette transporter A1 (ABCA1) and ABCG1 were quantified by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. The results indicated that IL-32α exposure enhanced the lipid deposition and attenuated the cholesterol efflux from ox-LDL-stimulated THP-1 macrophages in a dose-dependent manner. Furthermore, the expression levels of ABCA1, LXRα and PPARγ were dose-dependently decreased by IL-32α at the mRNA and protein levels. Addition of the PPARγ agonist 15d-PGJ2 or overexpression of PPARγ in THP-1 macrophages abrogated the IL-32α-mediated inhibition of cholesterol efflux and reversed the IL-32α-mediated downregulation of ABCA1 and LXRα. In conclusion, IL-32α enhances lipid accumulation and inhibits cholesterol efflux from ox-LDL-exposed THP-1 macrophages by regulating the PPARγ-LXRα-ABCA1 pathway.
Introduction
Atherosclerosis is a chronic metabolic disorder, which is characterized by the formation and accumulation of lipid plaques in the arteries and by inflammatory responses (1) (2) (3) (4) . The main lipid-laden cells are known as foam cells and are a key attribute of atherosclerotic lesions (2) (3) (4) . In atherosclerotic lesions, macrophages that express scavenger receptors on their plasma membranes uptake low-density lipoprotein (LDL) deposited into blood vessel walls, and are converted into foam cells. Foam cells can secrete various inflammatory cytokines and promote the development of atherosclerosis (5) . Therefore, preventing foam cell formation by decreasing cholesterol influx and increasing cholesterol efflux may be a potential treatment strategy for atherogenesis.
Macrophage-specific reverse cholesterol transport (RCT) is one of the most important high density lipoprotein (HDL)-mediated cardioprotective mechanisms (6) . RCT is a process during which cholesterol in peripheral cells is effluxed into circulating HDL and transported back into the liver for excretion in bile and feces (7) . The cholesterol efflux from cells to HDL is a rate-limiting step of RCT (8) . The family of ATP-binding cassette (ABC) transporters, including ABCA1 and ABCG1, has been demonstrated to serve a critical role in the RCT pathway by promoting the translocation of cholesterol across cellular bilayer membranes (9, 10) . ABCA1 enhances the cholesterol efflux to lipid-poor apolipoproteins, such as apolipoprotein A-I (apoAI), while ABCG1 increases the cholesterol efflux to HDL (11) . The expression levels of ABCA1 and ABCG1 are regulated, to a certain extent, by the peroxisome proliferator-activated receptor γ (PPARγ) and liver X receptor α (LXRα) (12) .
Interleukin-32 (IL-32) was originally identified as natural killer (NK) 5 transcript 4, induced by IL-18 in NK cells (13) . Due to its cytokine-like characteristics and its critical role in inflammation, it was renamed as IL-32 (13) . IL-32 is promoted by interferon-γ, IL-18 and IL-12 in various cell types, such as epithelial cells. In addition, it induces the production of various pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), IL-8, IL-1β and IL-6, as well as of numerous chemokines in monocytes and macrophages (13) . There are six isoforms of IL-32 by alternative splicing, namely IL-32α, IL-32β, IL32γ, IL-32δ, IL-32ε, and IL-32ζ (13), with IL-32α being the most abundant transcript (14) . As IL-32 is a pro-inflammatory cytokine, its effects on various inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, have been explored (15) . However, the role of IL-32 on cholesterol efflux remains unknown. In the present study, IL-32α was used to treat oxidized LDL (ox-LDL)-stimulated THP-1 macrophages in order to investigate the effects of IL-32α on cholesterol efflux.
Materials and methods
Cell culture. The human monocyte THP-1 cell line was purchased from the American Type Culture Collection (Manassas, VA, USA). THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum, 0.1% nonessential amino acids, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were incubated at 37˚C in a humidified atmosphere of 5% CO 2 . THP-1 cells were treated with 160 nmol/l phorbol 12-myristate 13-acetate (PMA) for 72 h and fully differentiated into macrophages. The differentiated THP-1 macrophages were then washed extensively with phosphate-buffered saline (PBS), and cells were incubated in serum-free medium containing 0.1% bovine serum albumin (BSA) and 50 µg/ml human ox-LDL (Anhui Yiyuan Biotechnology Co., Ltd., Anhui, China) for a further 48 h. All reagents for cell culture were obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). PMA was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Recombinant human IL-32α was obtained from R&D Systems (Minneapolis, MN, USA).
Morphological examination. THP-1 macrophages were incubated in chamber slides in serum-free medium (containing 0.1% BSA) with or without IL-32α (20, 50 , and 100 ng/ml) for 6 h, and then exposed to 50 µg/ml ox-LDL for 24 h. Cells were washed with PBS for three times, fixed with 5% formalin solution in PBS for 30 min, and stained with Oil Red O for a further 30 min. Subsequently, cells were counterstained with hematoxylin for 5 min. Finally, images of the stained cells were captured using a Leica optical microscope (Leica Microsystems GmbH, Wetzlar, Germany). The number of stained cells was counted in five random fields (magnification, x100) for each group.
Plasmid construction. The pcDNA3.1-PPAR-γ plasmid was constructed by inserting the human PPAR-γ cDNA (Genbank no., NM_138711.3) into a pcDNA3.1 mammalian expression vector. The full-length cDNA sequence was amplified using Takara Ex Taq DNA polymerase (Takara Bio, Inc., Otsu, Japan), according to the manufacturer's protocol. The primers used were as follows: PPAR-γ forward, 5'-GGGGGTACCATGACCATGGTTG-3' and reverse, 5'-GGGCTCGAGCTAGTACAAGTCC-3'. Thermocycling conditions were as follows: Initial denaturation at 95˚C for 5 min, followed by 35 cycles of 95˚C for 30 sec, 59˚C for 30 sec, and 72˚C for 45 sec. All constructs were sequenced to ensure accuracy.
Cell transfection. THP-1 macrophages (2x106 cells/well) were seeded in 6-well plates and incubated overnight prior to transfection. pcDNA3.1-PPAR-γ or pcDNA3.1 vector was added to each well at a final concentration of 50 nM and was incubated with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 30 min. The pcDNA3.1-transfected group served as a negative control.
Cholesterol efflux. THP-1 macrophages were assigned to the following groups: Untreated control, ox-LDL, ox-LDL+IL-32α, ox-LDL+15d-PGJ2, ox-LDL+DMSO, ox-LDL+IL-32α+15d-PGJ2, and ox-LDL+IL-32α+DMSO. THP-1 macrophages were cultured until they reached 60% confluence, and were then labeled with 0.2 µCi/ml [ 3 H] cholesterol (PerkinElmer, Inc., Waltham, MA, USA) for 24 h. Fresh serum-free medium with 0.1% BSA containing the PPARγ agonist 15d-PGJ2 (5 µM; Merck & Co., Inc., Whitehouse Station, NJ, USA) or 0.1% dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA) was added to THP-1 macrophages for 1 h, followed by exposure to IL-32α (50 ng/ml) for a further 6 h. Ox-LDL was then added to cells and incubated for another 24 h. Equilibrated 
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and 2 µg total RNA was used as the template for reverse transcription using a PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan) cDNA was used as template for qPCR on the Light Cycler system (Roche Diagnostics, Shanghai China) using SYBR-Green I Master mixture (Roche Diagnostics). Cycling conditions were as follows: Initial denaturation at 95˚C for 5 min, then 35 cycles of denaturation at 95˚C for 20 sec, annealing at 58˚C for 30 sec and extension at 72˚C for 50 sec. The primers used for qPCR in the present study were synthesized by Sangon Biotech (Shanghai, China) and are listed in Table I . β-actin was used as the housekeeping gene control for qPCR. The threshold cycle (Cq) values were used to calculate the fold change in transcript levels using the 2 -ΔΔCq method (16), as follows: Fold change=2- .
Western blot assay. Ox-LDL-stimulated THP-1 macrophages were washed with PBS for three times and lysed in lysis buffer (20 mM HEPES, 300 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl 2 and 1% Triton X-100) containing 2% phenylmethylsulfonyl fluoride. Total protein concentrations were measured with a Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Subsequently, 20 µg cell lysates were subjected to 10% SDS-polyacrylamide gel electrophoresis, and proteins were transferred to nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). Membranes were blocked with 5% non-fat milk for 1 h at room temperature and probed with antibodies against ABCA1 (sc-81779; 1:500 dilution), ABCG1 (sc-20795; 1:500 dilution), PPARγ (sc-6285; 1:500 dilution), LXRα (sc-1202; 1:500 dilution) and anti-human β-actin (sc-47778; 1:1,000 dilution; all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in antibody dilution buffer [5% non-fat milk in 1X Tris-buffered saline/0.1% Tween-20 (TBST)] at 4˚C overnight. Next, the membranes were washed with TBST for three times and then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (sc-2004; 1:2,000 dilution) or goat anti-mouse IgG (sc-2005; 1:1,000 dilution; Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. After washing with TBST, the membranes were subjected to an enhanced chemiluminescence advanced system (GE Healthcare Life Sciences, Chicago, IL, USA). β-actin was used as a loading control. The protein bands were analyzed using Quantity One software (version 4.6.2; Bio-Rad Laboratories Inc., Hercules, CA, USA).
Statistical analysis. SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA) was used to perform statistical analysis. Data are presented as the means ± standard deviation of three experiments, or are representative of experiments repeated at least three times. Comparisons were conducted with a one-way analysis of variance and post-hoc Tukey's tests. P<0.05 was considered to indicate a statistically significant difference.
Results

IL-32α induces lipid deposition in THP-1 macrophages.
The effect of IL-32α on lipid deposition in THP-1 macrophages was evaluated using Oil Red O staining. As shown in Fig. 1 , ox-LDL exposure significantly induced lipid accumulation in THP-1 macrophages, compared with the untreated control (P<0.05). Notably, addition of recombinant IL-32α protein significantly induced lipid deposition in ox-LDL-induced THP-1 macrophages in a concentration-dependent fashion.
IL-32α reduces cholesterol efflux.
The results indicated that the percentage of cholesterol efflux was significantly increased following ox-LDL exposure in THP-1 macrophages (P<0.05; Fig. 2 ). However, IL-32α treatment attenuated the apoA-I-mediated cholesterol efflux in a dose-dependent manner in ox-LDL-stimulated THP-1 macrophages, with a significant effect observed for the 50 and 100 ng/ml IL-32α doses (P<0.05; Fig. 2 ). This suggests that IL-32α increased intracellular lipid accumulation by decreasing the apoA-I-mediated cholesterol efflux.
IL-32α reduces the expression levels of ABCA1, LXRα and
PPARγ. The importance of ABCA1, ABCG1, LXRα and PPARγ in apoA-I-mediated cholesterol efflux has previously been established (13) . Therefore, the present study next analyzed the effects of IL-32α on the mRNA levels of these molecules by RT-qPCR in ox-LDL-stimulated THP-1 macrophages. The results demonstrated that ox-LDL treatment significantly raised the mRNA levels of ABCA1, LXRα and PPARγ, compared with untreated controls (P<0.05; Fig. 3A) . The addition of 100 ng/ml IL-32α significantly decreased the mRNA expression levels of ABCA1, LXRα and PPARγ by 59, 52.9 and 61.1%, respectively, compared with the ox-LDL alone group (P<0.05; Fig. 3A) . However, the level of ABCG1 was not affected. Subsequently, the study explored whether the IL-32α-mediated inhibition of ABCA1, LXRα and PPARγ mRNA expression led to decreased expression of ABCA1, LXRα and PPARγ protein using western blot analysis. As shown in Fig. 3B , IL-32α also suppressed the expression of ABCA1, LXRα and PPARγ at the protein level.
Overexpression of PPARγ rescued IL-32α-mediated inhibition of cholesterol efflux.
To evaluate the effects of PPARγ on IL-32α-mediated inhibition of cholesterol efflux, the PPARγ agonist 15d-PGJ2 was used to treat cells ( Fig. 4A and B) or pcDNA3.1-PPARγ ( Fig. 4C and D) was transfected to THP-1 macrophages. The 15d-PGJ2 treatment or overexpression of PPARγ significantly enhanced cholesterol efflux ( Fig. 4A and C) and increased the expression levels of ABCA1 and LXRα (Fig. 4B and D) in ox-LDL-stimulated THP-1 cells.
Discussion
In the present study, the effects of treatment with IL-32α, the most abundant transcript of the pro-inflammatory cytokine IL-32, were investigated in ox-LDL-stimulated THP-1 cells.
The results revealed that IL-32α increased lipid deposition and dose-dependently decreased the cholesterol efflux from ox-LDL-stimulated THP-1 macrophages. In addition, IL-32α attenuated the expression levels of ABCA1, LXRα and PPARγ.
To determine the mechanism of IL-32α-mediated inhibition of cholesterol efflux, PPARγ overexpression was performed in THP-1 macrophages by transfection. PPARγ overexpression abrogated the IL-32α-mediated inhibition of cholesterol efflux and reversed the IL-32α-mediated downregulation of ABCA1 and LXRα. Thus, it was demonstrated that IL-32α inhibits the cholesterol efflux from ox-LDL-exposed THP-1 macrophages by regulating the PPARγ-LXRα-ABCA1 pathway.
IL-32 was identified as NK cell transcript 4 (NK4), since it was selectively expressed in activated T cells or NK cells (17) . The biological role of IL-32 remained unclear until 2005, when Kim et al (13) demonstrated that recombinant NK4 was able to induce several pro-inflammatory cytokines, including TNF-α and IL-8. Therefore, NK4 was renamed to IL-32. The IL-32 gene has six splice variants, including IL-32α, IL-32β, IL32γ, IL-32δ, IL-32ε, and IL-32ζ (18), with IL-32α being the most abundant transcript (14) . IL-32 can induce a range of pro-inflammatory mediators and contribute to autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease (19) . Inflammation serves an important role in the initiation and progression of atherosclerosis and immune disease (20) . A range of immune cells, such as macrophages and T-lymphocytes, orchestrate the inflammatory response in atherosclerosis through the action of various cytokines (21) . However, the effects of IL-32α as an inflammatory cytokine in atherosclerosis remain unknown. The present study investigated the effects of IL-32α on lipid deposition and cholesterol efflux. As expected, IL-32α enhanced lipid deposition and inhibited cholesterol efflux in ox-LDL-stimulated THP-1 macrophages, which simulated a foam cell formation model. ABCA1 and ABCG1 are integral participants in cholesterol efflux and reverse cholesterol transport (21) . To investigate the mechanism of the IL-32α-mediated negative effects on cholesterol efflux, western blot analysis was conducted in the present study to explore the protein expression of ABCA1 and ABCG1. The results showed that IL-32α inhibited the expression of ABCA1, but did not affect the expression of ABCG1, indicating that IL-32α inhibits cholesterol efflux through the ABCA1 signaling pathway. PPARγ and LXRα are nuclear receptors that serve a pivotal role in macrophage cholesterol homeostasis and inflammation (22) . Western blot analysis in the current study demonstrated that IL-32α attenuated the expression levels of PPARγ and LXRα. These results indicate that IL-32α may inhibit cholesterol efflux through the PPARγ-LXRα-ABCA1 signaling pathway.
Inflammatory cytokines are involved in all stages of atherosclerosis and have a profound influence on the pathogenesis of atherosclerosis, including cholesterol efflux. IL-6 and TNF-α inhibit cholesterol efflux by suppressing ABCA1 expression (23) . IL-1β has been demonstrated to promote lipid accumulation and inhibit cholesterol efflux in human mesangial cells by dysregulating the expression of lipoprotein receptors, thus inhibiting cholesterol efflux through the PPAR-LXRα-ABCA1 pathway (24) . Furthermore, PPARγ agonists protect mesangial cells from IL-1β-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway (24) . To further investigate the role of PPARγ on IL-32α-meidated inhibition of cholesterol efflux, the present study demonstrated that the PPARγ agonist 15d-PGJ2 and PPARγ overexpression through transfection enhanced cholesterol efflux in ox-LDL-stimulated THP-1 macrophages. These findings indicate that inhibition of PPARγ serves an important role in IL-32α-mediated suppression of cholesterol efflux.
In conclusion, the present study demonstrated that IL-32α promotes lipid deposition and inhibits cholesterol efflux through the suppression of PPARγ-LXRα-ABCA1 signaling pathway in ox-LDL-stimulated THP-1 macrophages. However, the role of other isoforms exclusive of IL-32α in cholesterol efflux remains unknown. Therefore, more studies are required to determine the function of each IL-32 isoform in lipid accumulation and cholesterol efflux.
